It was an honor to meet Professor Mads Krogsgaard Thomsen to discuss the results from seven phase 3a PIONEER clinical trials for oral semaglutide in patients with type 2 diabetes, including the cardiovascular outcomes trial (PIONEER 6) at the highly anticipated symposium highlighted by the ADA 2019 annual meeting.
Filmed at the American Diabetes Association (ADA) annual meeting 2019, San Francisco, USA
1. What are the advantages of oral semaglutide compared to existing glucagon-like peptide-1 (GLP-1) analogues? (0:05)
2. Could you give us an overview on the data on oral semaglutide that are being presented at this meeting? (0:36)
3. What were the findings of oral semaglutide on weight loss? (1:37)
4. The PIONEER studies investigated a number of combined therapeutic approaches. Which were the most promising? (2:24)
5. Which patients are most likely to benefit from oral semaglutide? (3:12)
Professor Mads Krogsgaard Thomsen has no conflicts of interest in relation to this video.
touchENDO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021: Anticipated Congress Highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20) What have we learned about the […]
IDF Virtual 2021 – Diabetes Complications and Covid-19
The International Diabetes Federation will organise a Virtual Congress on December 6-11, 2021. It will feature the latest research on diabetes complications and sessions dedicated to COVID-19 and diabetes, the centenary of insulin and the IDF Diabetes Atlas 10th Edition. Discover the Congress at https://idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!